Novartis UK HCP Portal
Published on Novartis UK HCP Portal (https://www.health.novartis.co.uk)

Home > Printer-friendly > Resources

Resources [1]

Resources designed to support KISQALI prescribers.

 

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Preview or download resources designed to support KISQALI prescribers. If you would like to get more information or receive copies of any materials, please contact a Novartis representative.

Treatment management

 

Your Choice with KISQALI logo

YOUR CHOICE WITH KISQALI

Your Choice is a dedicated support programme designed to facilitate monitoring of KISQALI patients in day-to-day practice.

Find out more [2] Download guide [3]

 

 

Preview of therapy management guide

THERAPY MANAGEMENT GUIDE

This guide provides information for healthcare professionals about how to use KISQALI, detailing posology, monitoring and managing adverse events.

Download [4]

 

 

Patient materials

 

Preview of patient information booklet: KISQALI + AI

PATIENT INFORMATION BOOKLET: KISQALI + AROMATASE INHIBITOR (AI)

This booklet provides information for patients about what to expect from treatment with KISQALI + AI.

Download [5]

 

 

Preview of patient information booklet: KISQALI + fulvestrant

PATIENT INFORMATION BOOKLET: KISQALI + FULVESTRANT

This booklet provides information for patients about what to expect from treatment with KISQALI + fulvestrant.

Download [6]

 

 

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1

Reference

  1. KISQALI® (ribociclib) Summary of Product Characteristics.

Source URL: https://www.health.novartis.co.uk/resources-and-training/oncology/kisqali/resources

Links
[1] https://www.health.novartis.co.uk/resources-and-training/oncology/kisqali/resources
[2] https://www.health.novartis.co.uk/resources-and-training/oncology/kisqali/resources/your-choice
[3] https://www.health.novartis.co.uk/sites/health.novartis.co.uk/files/your_choice_with_kisqali.pdf?v=1
[4] https://www.health.novartis.co.uk/sites/health.novartis.co.uk/files/kisqali_therapy_management_guide.pdf
[5] https://www.health.novartis.co.uk/sites/health.novartis.co.uk/files/your_guide_to_treatment_kisqali_ai.pdf
[6] https://www.health.novartis.co.uk/sites/health.novartis.co.uk/files/your_guide_to_treatment_kisqalifulvestrant.pdf